Eastern Cooperative Oncology Group classification and its application in surgical treatment planning of epithelial ovarian cancer - Report - MDSpire

Eastern Cooperative Oncology Group classification and its application in surgical treatment planning of epithelial ovarian cancer

  • By

  • Siiri Karjalainen

  • Auni Lindgren

  • Merja Kokki

  • Julia Heikkinen

  • Maarit Anttila

  • July 9, 2026

  • 0 min

Share

Utilization of Eastern Cooperative Oncology Group Classification in Developing Surgical Treatment Strategies for Epithelial Ovarian Cancer

Overview

This study evaluates the association of ECOG classification with patient performance status and its role in surgical decision-making for epithelial ovarian cancer.

Background

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer, often diagnosed at advanced stages. Accurate assessment of patients' physical performance is crucial for determining their suitability for surgical interventions. The ECOG classification serves as a tool in this assessment.

Data Highlights

ECOG GroupNumber of PatientsSurvival Rate (p-value)Hazard Ratio (HR)
0129 (56.6%)0.0033.785
176 (33%)0.00510.231
2-423 (10.1%)0.00210.231

Key Findings

  • 129 patients (56.6%) were classified as ECOG 0, 76 (33%) as ECOG 1, and 23 (10.1%) as ECOG 2-4.
  • Lower ECOG scores were associated with higher survival rates after surgery.
  • Age, self-reported walking distance, stair climbing capacity, ASA classification, albumin, prealbumin, and number of comorbidities were significantly associated with ECOG groups.
  • ECOG classification was not linked to postoperative complications or length of hospital stay.

Clinical Implications

The ECOG classification can aid clinicians in evaluating patients' physical status for surgical interventions for EOC.

Conclusion

ECOG classification is a useful tool for assessing physical performance status in patients with EOC.

Related Resources & Content

  1. ASCO Post, ASCO Publishes Resource-Stratified Guideline on Assessment and Treatment of Ovarian Cancer, 2021 -- ASCO Publishes Resource-Stratified Guideline on Assessment and Treatment of Ovarian Cancer
  2. European Radiology, ESR Perspectives: Imaging and Management Strategies for Ovarian Cancer from a Multidisciplinary Approach -- Imaging and Management Strategies for Ovarian Cancer
  3. Frontiers in Oncology, Surgical treatment and prognosis in patients with intestinal metastases originated from advanced epithelial ovarian cancer -- Surgical treatment and prognosis in patients with intestinal metastases originated from advanced epithelial ovarian cancer
  4. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update - PMC -- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
  5. EORTC Trial 55971 Compares Treatment Options For Patients With Stage IIIC Or IV Ovarian Carcinoma - EORTC -- EORTC Trial 55971 Compares Treatment Options For Patients With Stage IIIC Or IV Ovarian Carcinoma
  6. European Radiology — Revised Guidelines for Staging and Monitoring Ovarian Cancer from the European Society of Urogenital Radiology's Female Pelvic Imaging Group
  7. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update - PMC
  8. EORTC Trial 55971 Compares Treatment Options For Patients With Stage IIIC Or IV Ovarian Carcinoma - EORTC
  9. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | New England Journal of Medicine

Original Source(s)

Related Content